COMPARISON OF 5FU-BASE CHEMORADIATION WITH AND WITHOUT ELOXATIN ON PATHOLOGIC COMPLETE RESPONSE IN NEOADJUVANT CHEMO-RADIATION OF RECTAL CANCER

摘要

Background and Objectives: To compare pathologic complete response (PCR) in patients with advanced rectal cancer receiving neoadjuvant chemoradiotherapy (NACT) by 5-FU or Xeloda (capecitabine) with and without Eloxatin (oxaloplatin injection).Materials and Methods: Seventy-five consecutive patients with the diagnosis of advanced rectal adenocarcinoma were included. Two basic chemotherapy regimens were used: one drug (5-FU or Xeloda) or two-drug (5-U or Xeloda with Eloxatin). Endpoints were PCR and preservation of sphincter during surgery through low anterior resection (LAR). All analyses were done using SPSS software version 17.0 (SPSS Inc., Chicago, IL).Results: There were no significant differences between the group of patients who received onedrug regimen with those who received two-drug regimen regarding the pCR (four cases (23.5%) versus 25 vases (43.1%)) state or the type of surgery performed [nine cases (52.9%) versus 36 cases (62.1%)].Conclusion: Adding Eloxatin to the standard treatment of rectal adenocarcinoma (5-FU based) did not yield in a higher PCR or a higher chance to preserve the anal sphincter.